NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease ; volume:14 ; number:1 ; day:23 ; month:4 ; year:2014 ; pages:1-8 ; date:12.2014
BMC gastroenterology ; 14, Heft 1 (23.4.2014), 1-8, 12.2014
- Urheber
-
Del Ben, Maria
- Beteiligte Personen und Organisationen
-
Polimeni, Licia
Carnevale, Roberto
Bartimoccia, Simona
Nocella, Cristina
Baratta, Francesco
Loffredo, Lorenzo
Pignatelli, Pasquale
Violi, Francesco
Angelico, Francesco
SpringerLink (Online service)
- DOI
-
10.1186/1471-230X-14-81
- URN
-
urn:nbn:de:1111-2016081214467
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:05 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Del Ben, Maria
- Polimeni, Licia
- Carnevale, Roberto
- Bartimoccia, Simona
- Nocella, Cristina
- Baratta, Francesco
- Loffredo, Lorenzo
- Pignatelli, Pasquale
- Violi, Francesco
- Angelico, Francesco
- SpringerLink (Online service)
Ähnliche Objekte (12)
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease
Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis